Cargando…

The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with molecular heterogeneity, inducing differences in biological behavior, and therapeutic strategy. NGS profiles of pathogenic alterations in the Chinese PDAC population are limited. We conducted a retrospective study to investi...

Descripción completa

Detalles Bibliográficos
Autores principales: Shui, Lin, Li, Xiaofen, Peng, Yang, Tian, Jiangfang, Li, Shuangshuang, He, Du, Li, Ang, Tian, Bole, Li, Mao, Gao, Heli, An, Ning, Yi, Cheng, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273977/
https://www.ncbi.nlm.nih.gov/pubmed/34247626
http://dx.doi.org/10.1186/s12967-021-02972-6
_version_ 1783721478086197248
author Shui, Lin
Li, Xiaofen
Peng, Yang
Tian, Jiangfang
Li, Shuangshuang
He, Du
Li, Ang
Tian, Bole
Li, Mao
Gao, Heli
An, Ning
Yi, Cheng
Cao, Dan
author_facet Shui, Lin
Li, Xiaofen
Peng, Yang
Tian, Jiangfang
Li, Shuangshuang
He, Du
Li, Ang
Tian, Bole
Li, Mao
Gao, Heli
An, Ning
Yi, Cheng
Cao, Dan
author_sort Shui, Lin
collection PubMed
description BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with molecular heterogeneity, inducing differences in biological behavior, and therapeutic strategy. NGS profiles of pathogenic alterations in the Chinese PDAC population are limited. We conducted a retrospective study to investigate the predictive role of DNA damage repair (DDR) mutations in precision medicine. METHODS: The NGS profiles were performed on resected tissues from 195 Chinese PDAC patients. Baseline clinical or genetic characteristics and survival status were collected. The Kaplan–Meier survival analyses were performed by the R version 3.6.1. RESULTS: The main driver genes were KRAS, TP53, CDKN2A, and SMAD4. Advanced patients with KRAS mutation showed a worse OS than KRAS wild-type (p = 0.048). DDR pathogenic deficiency was identified in 30 (15.38%) of overall patients, mainly involving BRCA2 (n = 9, 4.62%), ATM (n = 8, 4.10%) and RAD50 genes (n = 3, 1.54%). No significance of OS between patients with or without DDR mutations (p = 0.88). But DDR mutation was an independent prognostic factor for survival analysis of advanced PDAC patients (p = 0.032). For DDR mutant patients, treatment with platinum-based chemotherapy (p = 0.0096) or olaparib (p = 0.018) respectively improved the overall survival. No statistical difference between tumor mutation burden (TMB) and DDR mutations was identified. Treatment of PD-1 blockades did not bring significantly improved OS to DDR-mutated patients than the naive DDR group (p = 0.14). CONCLUSIONS: In this retrospective study, we showed the role of germline and somatic DDR mutation in predicting the efficacy of olaparib and platinum-based chemotherapy in Chinese patients. However, the value of DDR mutation in the prediction of hypermutation status and the sensitivity to the PD-1 blockade needed further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02972-6.
format Online
Article
Text
id pubmed-8273977
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82739772021-07-13 The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma Shui, Lin Li, Xiaofen Peng, Yang Tian, Jiangfang Li, Shuangshuang He, Du Li, Ang Tian, Bole Li, Mao Gao, Heli An, Ning Yi, Cheng Cao, Dan J Transl Med Research BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with molecular heterogeneity, inducing differences in biological behavior, and therapeutic strategy. NGS profiles of pathogenic alterations in the Chinese PDAC population are limited. We conducted a retrospective study to investigate the predictive role of DNA damage repair (DDR) mutations in precision medicine. METHODS: The NGS profiles were performed on resected tissues from 195 Chinese PDAC patients. Baseline clinical or genetic characteristics and survival status were collected. The Kaplan–Meier survival analyses were performed by the R version 3.6.1. RESULTS: The main driver genes were KRAS, TP53, CDKN2A, and SMAD4. Advanced patients with KRAS mutation showed a worse OS than KRAS wild-type (p = 0.048). DDR pathogenic deficiency was identified in 30 (15.38%) of overall patients, mainly involving BRCA2 (n = 9, 4.62%), ATM (n = 8, 4.10%) and RAD50 genes (n = 3, 1.54%). No significance of OS between patients with or without DDR mutations (p = 0.88). But DDR mutation was an independent prognostic factor for survival analysis of advanced PDAC patients (p = 0.032). For DDR mutant patients, treatment with platinum-based chemotherapy (p = 0.0096) or olaparib (p = 0.018) respectively improved the overall survival. No statistical difference between tumor mutation burden (TMB) and DDR mutations was identified. Treatment of PD-1 blockades did not bring significantly improved OS to DDR-mutated patients than the naive DDR group (p = 0.14). CONCLUSIONS: In this retrospective study, we showed the role of germline and somatic DDR mutation in predicting the efficacy of olaparib and platinum-based chemotherapy in Chinese patients. However, the value of DDR mutation in the prediction of hypermutation status and the sensitivity to the PD-1 blockade needed further investigation. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-021-02972-6. BioMed Central 2021-07-12 /pmc/articles/PMC8273977/ /pubmed/34247626 http://dx.doi.org/10.1186/s12967-021-02972-6 Text en © The Author(s) 2021, corrected publication 2021 https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Shui, Lin
Li, Xiaofen
Peng, Yang
Tian, Jiangfang
Li, Shuangshuang
He, Du
Li, Ang
Tian, Bole
Li, Mao
Gao, Heli
An, Ning
Yi, Cheng
Cao, Dan
The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
title The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
title_full The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
title_fullStr The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
title_full_unstemmed The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
title_short The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma
title_sort germline/somatic dna damage repair gene mutations modulate the therapeutic response in chinese patients with advanced pancreatic ductal adenocarcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8273977/
https://www.ncbi.nlm.nih.gov/pubmed/34247626
http://dx.doi.org/10.1186/s12967-021-02972-6
work_keys_str_mv AT shuilin thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT lixiaofen thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT pengyang thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT tianjiangfang thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT lishuangshuang thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT hedu thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT liang thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT tianbole thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT limao thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT gaoheli thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT anning thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT yicheng thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT caodan thegermlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT shuilin germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT lixiaofen germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT pengyang germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT tianjiangfang germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT lishuangshuang germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT hedu germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT liang germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT tianbole germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT limao germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT gaoheli germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT anning germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT yicheng germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma
AT caodan germlinesomaticdnadamagerepairgenemutationsmodulatethetherapeuticresponseinchinesepatientswithadvancedpancreaticductaladenocarcinoma